Chen Wei’s team’s vaccine releases Phase III data experts: suitable for rapid mass vaccination

Chen Wei's team finally announced the third phase of this vaccine. Experts: single injection is highly effective and suitable for rapid mass vaccination

　　[Global Times-Global.com Reporter Zhao Juehui, Bai Yunyi, Hu Yuwei] Following the release of Phase III clinical data for two inactivated vaccines of Sinopharm Group, Sinopharm and Coxing Zhongwei, another technical route for the deployment of China’s new crown vaccine was established by Chen from the Academy of Military Sciences. The latest data on the adenoviral vector vaccine Ad5-nCoV jointly developed by the team of Academician Wei and Cansino Biology was released.

Pakistani health officials announced on the same day that the results of the interim analysis of the Phase III clinical trial of Ad5-nCoV in Pakistan showed that after a single injection, the vaccine has a protective effect of 100% against severe new coronary pneumonia and an overall protective effect of 74.8%.

　　The Ad5-nCoV vaccine developed by Chen Wei’s team is the world’s first new coronavirus vaccine that has entered the clinical research stage, and is currently one of the only single-dose vaccines in the world that has released Phase III trial data. Several experts told reporters from the Global Times, The effective rate of this vaccine is very good, and single-dose vaccination means that large-scale and rapid population vaccination can be achieved, which is of great significance to the overall epidemic prevention strategy of society.

　　Pakistan’s special assistant to the prime minister for national health affairs, Feisuo Sudan, said on the 8th local time that Ad5-nCoV (also known as “Kwisha” or “Convidecia”) conducted an interim analysis of the Phase III clinical trial in Pakistan. 28 days after vaccination, the vaccine's protective efficacy against severe new coronary pneumonia was 100%, and the overall protective efficacy was 74.8%. There were no serious adverse reactions related to the vaccine.

　　The above-mentioned officials also revealed that the global Phase III clinical trial data of Ad5-nCoV showed that 28 days after a single injection of the vaccine, the vaccine's protective efficacy against severe new coronary pneumonia was 90.98%, and the overall protective efficacy was 65.7%.

According to the announcement issued by CanSino Bio on the 1st, the Phase III clinical trial of Ad5-nCoV has completed the inoculation of more than 40,000 subjects in 78 clinical research centers in 5 countries.

It is reported that the countries where Ad5-nCoV is undergoing Phase III clinical trials include Mexico, Russia, Pakistan, Argentina and Chile.

　　Ad5-nCoV was developed by the team of Academician Chen Wei from the Institute of Bioengineering of the Academy of Military Medical Sciences of the Academy of Military Sciences and Cansino Bio. The Phase I and Phase II clinical trials were launched in Wuhan on March 16 and April 12 last year respectively. The world's first new crown vaccine to enter the clinical research phase.

The clinical trial results preliminarily proved the safety of the vaccine, and the data of the two-phase clinical trials were published in the internationally renowned medical journal "The Lancet".

　　A Chinese expert in immunology told the Global Times reporter on the 8th that Ad5-nCoV's effective rate data is very good, especially considering that it is one of the few single-dose new crown vaccines, in the absence of a second dose of enhanced effect Therefore, the neutralizing antibody titer is difficult to reach a high level.

"If you have to compare horizontally, the effectiveness of Ad5-nCoV should be compared with the data after the first shot of other vaccines." Professionals in the vaccine field Zhuang Shili and doctors also told the Global Times reporter on the same day, although from the surface The overall effective rate of the vaccine seems to be lower than that of other adenovirus vector vaccines, but an important prerequisite must be considered, that is, Cansino vaccine is one of the rare single-dose vaccines.

　　At present, the global and CanSino vaccines that use the same technical route to develop also include Oxford/AstraZeneca vaccine (AZD1222), Johnson & Johnson vaccine (Ad26.COV2.S) and Russia's "Satellite V", of which only CanSino vaccine and Johnson & Johnson vaccine The vaccine is a single shot vaccine.

On January 29 this year, Johnson & Johnson announced that the results of the Phase III clinical trial of its vaccine showed that 28 days after a single dose of the new crown vaccine, the total effective rate against moderate and severe new coronary pneumonia reached 66%, preventing serious diseases in all research areas The effective rate is 85%.

In contrast, although the Johnson & Johnson vaccine is also a single shot, its effective rate of 66% is not mild, and its 85% preventive effect of severe illness is not as good as that of Ad5-nCoV 90.98%.

　　"Specifically, among the adenovirus vector vaccines, the Oxford/AstraZeneca vaccine data is rather confusing. Overall, the double injection efficiency is not high, only 70%; the data of the Russian'satellite V'vaccine is relatively optimistic. The overall effective rate of the injection is 91.6%, which is the only adenovirus vector vaccine with an overall effective rate of more than 90%. In addition, according to his paper published in The Lancet, the effective rate after the first injection of'Satellite V' 73.1% is also a very good figure. Overall, the single shot of Cansino vaccine can reach 65.7%, which is a very good result." said Zhuang Shilihe.

　　The above-mentioned immunology experts analyzed that the single-dose vaccination procedure is simple and can inoculate more people in the same time period, which is beneficial to protect as many people as possible in the shortest time.

Zhuang Shilihe also believes that Ad5-nCoV can achieve rapid mass vaccination of the population, and the 90% critical illness prevention rate means that the pressure on hospital beds can be greatly reduced.

It is understood that another advantage of Cansino vaccine is that it only needs to be stored at 2 to 8 degrees Celsius, suitable for transportation and distribution.

　　However, the data released by Pakistan this time did not mention whether the effectiveness of Cansino vaccine will be affected by virus mutation.

Previously, Johnson & Johnson, AstraZeneca, etc. have reported that the vaccine's protective efficacy against South African mutant strains has been reduced.

In addition, an immunologist interviewed by the Global Times added that it is necessary to further observe the adverse reaction data of the Cansino vaccine, because the adenovirus vector vaccine is essentially similar to a cold virus and may cause some cold symptoms during the vaccination process. Whether it is recommended for people with weaker health to receive such vaccines needs further observation.